Kiyaros-Gold 10 Capsule is a combination pharmaceutical formulation containing Aspirin (75mg), Rosuvastatin (10mg), and Clopidogrel (75mg), designed for the management and prevention of cardiovascular diseases. Aspirin, an antiplatelet agent, inhibits cyclooxygenase enzymes, thereby reducing thromboxane A2 production and preventing platelet aggregation. Clopidogrel, another antiplatelet agent, irreversibly inhibits the P2Y12 component of ADP receptors on platelet surfaces, further reducing platelet activation and aggregation. Rosuvastatin, a potent HMG-CoA reductase inhibitor, effectively lowers low-density lipoprotein cholesterol (LDL-C) and triglycerides while modestly increasing high-density lipoprotein cholesterol (HDL-C), contributing to the reduction of atherosclerotic plaque formation. This combination is primarily indicated for patients at high risk of thrombotic cardiovascular events, including those with a history of myocardial infarction, stroke, or established peripheral arterial disease. The synergistic action of these agents helps in secondary prevention by reducing the risk of recurrent ischemic events. Kiyaros-Gold 10 Capsule should be administered under medical supervision, considering potential contraindications such as active bleeding, hypersensitivity, or severe hepatic impairment. Regular monitoring of liver function, renal function, and hematological parameters is recommended during therapy to ensure safety and efficacy.